Detalles de la búsqueda
1.
iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
Diabetes Obes Metab;
25(7): 2005-2011, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36999231
2.
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
Diabetes Obes Metab;
24(12): 2391-2399, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36054624
3.
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
Diabetes Obes Metab;
24(11): 2182-2191, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762489
4.
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Diabetes Obes Metab;
24(8): 1522-1533, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35441412
5.
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
Diabetes Obes Metab;
24(1): 34-41, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34617398
6.
Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
Diabetes Ther;
13(1): 205-215, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34894329
7.
Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy.
Diabetes Ther;
12(12): 3231-3241, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34714524
8.
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
Diabetes Obes Metab;
23(6): 1331-1341, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33565209
9.
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.
Diabetes Care;
44(3): 774-780, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33468520
10.
Impact of disease duration and ß-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
Diabetes Obes Metab;
22(9): 1567-1576, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32323437
11.
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
Diabetes Care;
42(11): 2108-2116, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31530665
12.
Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.
J Diabetes Complications;
33(3): 236-242, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30600136
13.
Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
Curr Med Res Opin;
35(6): 1081-1089, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30550345
14.
iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.
Diabetes Ther;
9(1): 373-382, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29143919
15.
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
Diabetes Obes Metab;
19(12): 1798-1804, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28432746
16.
Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980.
Diabetes Care;
40(6): 809, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28428368
17.
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
Diabetes Obes Metab;
19(10): 1408-1415, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28386990
18.
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035.
Diabetes Care;
40(6): 809, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28420696
19.
Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring.
Diabetes Metab Res Rev;
33(4)2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28032465
20.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
Diabetes Care;
39(11): 1972-1980, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27650977